Percutaneous left ventricular assist devices for high-risk percutaneous coronary intervention

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 9, 2010, Pages 1247-1255

  Engström, Annemarie E ^a   Piek, Jan J ^a   Henriques, José P S ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

coronary artery disease; elective percutaneous revascularization; mechanical circulatory support; reduced left ventricular function

Indexed keywords

ASSISTED CIRCULATION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; EXTRACORPOREAL OXYGENATION; HEART ASSIST DEVICE; HEART LEFT VENTRICLE FUNCTION; HYPOTENSION; PERCUTANEOUS CORONARY INTERVENTION; REVIEW;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ANGIOGRAPHY; HEART-ASSIST DEVICES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77956512819     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.93     Document Type: Review

References (42)

1. Favaloro RG. Saphenous vein autograft replacement of severe segmental coronary artery occlusion: operative technique. Ann. Thorac. Surg. 5(4), 334-339 (1968).
2. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1(8058), 263 (1978).
3. Daemen J, Boersma E, Flather M et al. Long-term safety and effcacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials. Circulation 118(11), 1146-1154 (2008).
4. Stettler C, Wandel S, Allemann S et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370(9591), 937-948 (2007).
5. Onuma Y, Serruys PW, Kukreja N et al. Randomized comparison of everolimus-and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials. Eur. Heart J. 31(9), 1071-1078 (2010).
6. Smith SC Jr, Feldman TE, Hirshfeld JW Jr et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J. Am. Coll. Cardiol. 47(1), e1-e121 (2006).
7. Serruys PW, Morice MC, Kappetein AP et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N. Engl. J. Med. 360(10), 961-972 (2009).
8. Kushner FG, Hand M, Smith SC Jr et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 120(22), 2271-2306 (2009).
9. Claessen BE, Stone GW, Smits P et al. Would SYNTAX have been a positive trial if XIENCE V was used instead of TAXUS? A meta-analysis of a frst generation vs. a second generation drug eluting stent system. Neth. Heart J. (2010) (In Press).
10. Wallace TW, Berger JS, Wang A, Velazquez EJ, Brown DL. Impact of left ventricular dysfunction on hospital mortality among patients undergoing elective percutaneous coronary intervention. Am. J. Cardiol. 103(3), 355-360 (2009).
11. Scherer M, Moritz A, Martens S. The use of extracorporeal membrane oxygenation in patients with therapy refractory cardiogenic shock as a bridge to implantable left ventricular assist device and perioperative right heart support. J. Artif. Organs 12(3), 160-165 (2009).
12. Aziz TA, Singh G, Popjes E et al. Initial experience with CentriMag extracorporal membrane oxygenation for support of critically ill patients with refractory cardiogenic shock. J. Heart Lung Transplant. 29(1), 66-71 (2010).
13. Formica F, Avalli L, Colagrande L et al. Extracorporeal membrane oxygenation to support adult patients with cardiac failure: predictive factors of 30-day mortality. Interact. Cardiovasc. Thorac. Surg 10(5), 721-726 (2010).
14. Rastan AJ, Dege A, Mohr M et al. Early and late outcomes of 517 consecutive adult patients treated with xtracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock. J. Thorac. Cardiovasc. Surg. 139(2), 302-311 (2010).
15. Ricciardi MJ, Moscucci M, Knight BP, Zivin A, Bartlett RH, Bates ER. Emergency extracorporeal membrane oxygenation (ECMO)-supported percutaneous coronary interventions in the fbrillating heart. Catheter. Cardiovasc. Interv. 48(4), 402-405 (1999).
16. Shammas NW, Roberts S, Early G. Extracorporeal membrane oxygenation for unprotected left main stenting in a patient with totally occluded right coronary artery and severe left ventricular dysfunction. J. Invasive Cardiol. 14(12), 756-759 (2002).
17. Reitan O, Ohlin H, Peterzen B, Granfeldt H, Steen S, Emanuelsson H. Initial tests with a new cardiac assist device. ASAIO J. 45(4), 317-321 (1999).
18. Reitan O, Steen S, Ohlin H. Hemodynamic effects of a new percutaneous circulatory support device in a left ventricular failure model. ASAIO J. 49(6), 731-736 (2003).
19. Smith EJ, Reitan O, Keeble T, Dixon K, Rothman MT. A frst-in-man study of the Reitan catheter pump for circulatory support in patients undergoing high-risk percutaneous coronary intervention. Catheter. Cardiovasc. Interv. 73(7), 859-865 (2009).
20. Kantrowitz A, Tjonneland S, Freed PS, Phillips SJ, Butner AN, Sherman JL Jr. Initial clinical experience with intraaortic balloon pumping in cardiogenic shock. JAMA 203(2), 113-118 (1968).
21. Sjauw KD, Engstrom AE, Vis MM et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur. Heart J. 30(4), 459-468 (2009).
22. Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J. Am. Coll. Cardiol. 44(3), E1-E211 (2004).
23. Briguori C, Sarais C, Pagnotta P et al. Elective versus provisional intra-aortic balloon pumping in high-risk percutaneous transluminal coronary angioplasty Am. Heart J. 145(4), 700-707 (2003).
24. Briguori C, Airoldi F, Chieffo A et al. Elective versus provisional intraaortic balloon pumping in unprotected left main stenting. Am. Heart J. 152(3), 565-572 (2006).
25. Mishra S, Chu WW, Torguson R et al. Role of prophylactic intra-aortic balloon pump in high-risk patients undergoing percutaneous coronary intervention. Am. J. Cardiol. 98(5), 608-612 (2006).
26. Perera D, Stables R, Thomas M et al. Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention, a randomized controlled trial. JAMA 304(8), 867-874 (2010).
27. Bogaev R, Civitello A. Mechanical support for heart failure. Presented at: Mechanical support for Heart Failure, satellite symposium of the American College of Cardiology 55 th Annual Scientifc Session. Atlanta, GA, USA, 11-14 March 2006.
28. Burkhoff D, Cohen H, Brunckhorst C, O'Neill WW. A randomized multicenter clinical study to evaluate the safety and effcacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am. Heart J. 152(3), 469-1468 (2006).
29. Thiele H, Sick P, Boudriot E et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur. Heart J. 26(13), 1276-1283 (2005).
30. Aragon J, Lee MS, Kar S, Makkar RR. Percutaneous left ventricular assist device: 'TandemHeart' for high-risk coronary intervention. Catheter. Cardiovasc. Interv. 65(3), 346-352 (2005).
31. Vranckx P, Meliga E, De Jaegere PP, Van den Ent M, Regar ES, Serruys PW The TandemHeart, percutaneous transseptal left ventricular assist device: a safeguard in high-risk percutaneous coronary interventions. The six-year Rotterdam experience. EuroIntervention 4(3), 331-337 (2008).
32. Kar B, Forrester M, Gemmato C et al. Use of the TandemHeart percutaneous ventricular assist device to support patients undergoing high-risk percutaneous coronary intervention. J. Invasive Cardiol. 18(3), 93-96 (2006).
33. Piazza N, Serruys PW, de Jaegere P. Feasibility of complex coronary intervention in combination with percutaneous aortic valve implantation in patients with aortic stenosis using percutaneous left ventricular assist device (TandemHeart). Catheter. Cardiovasc. Interv. 73(2), 161-166 (2009).
34. Sjauw KD, Remmelink M, Baan J Jr et al. Left ventricular unloading in acute ST-segment elevation myocardial infarction patients is safe and feasible and provides acute and sustained left ventricular recovery. J. Am. Coll. Cardiol. 51(10), 1044-1046 (2008).
35. Seyfarth M, Sibbing D, Bauer I et al. A randomized clinical trial to evaluate the safety and effcacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J. Am. Coll. Cardiol. 52(19), 1584-1588 (2008).
36. Henriques JP, Remmelink M, Baan J Jr et al. Safety and feasibility of elective high-risk percutaneous coronary intervention procedures with left ventricular support of the Impella Recover LP 2.5. Am. J. Cardiol. 97(7), 990-992 (2006).
37. Burzotta F, Paloscia L, Trani C et al. Feasibility and long-term safety of elective Impella-assisted high-risk percutaneous coronary intervention: a pilot two-centre study. J. Cardiovasc. Med. (Hagerstown) 9(10), 1004-1010 (2008).
38. Dixon SR, Henriques JP, Mauri L et al. A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (the PROTECT I trial): initial U.S. experience. JACC Cardiovasc. Interv. 2(2), 91-96 (2009).
39. Sjauw KD, Konorza T, Erbel R et al. Supported high-risk percutaneous coronary intervention with the Impella 2.5 device the Europella registry. J. Am. Coll. Cardiol. 54(25), 2430-2434 (2009).
40. Tuseth V, Pettersen RJ, Epstein A et al. Percutaneous left ventricular assist device can prevent acute cerebral ischaemia during ventricular fbrillation. Resuscitation 80(10), 1197-1203 (2009).
41. Tuseth V, Salem M, Pettersen R et al. Percutaneous left ventricular assist in ischemic cardiac arrest. Crit. Care Med. 37(4), 1365-1372 (2009).
42. Lam K, Sjauw KD, Henriques JP, Ince C, de Mol BA. Improved microcirculation in patients with an acute ST-elevation myocardial infarction treated with the Impella LP2.5 percutaneous left ventricular assist device. Clin. Res. Cardiol. 98(5), 311-318 (2009).